CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 150 enrolled
Drug / intervention
OraVerse +1 moredrug
Likely dose
OraVerse 1.8mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01474382
NCT01474382Phase 4Completed

A Phase 4, Multicenter, Randomized, Double-Blinded, Controlled Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients Undergoing Mandibular and Maxillary Procedures

Novocol Pharmaceutical of Canada, Inc.·interventional·Posted Nov 18, 2011·Updated Aug 29, 2014

In Brief

A Phase 4 clinical trial evaluating OraVerse and Sham injection for Dental Anesthesia and 2 related conditions. Completed, enrolled 150 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine whether OraVerse is safe and effective for the reversal of dental anesthesia in children 2 to 5 years of age weighing at least 10 kg.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2011
Enrollment StartFeb 1, 2012
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.6 years ago

Interventions

OraVersedrug

1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight

Sham injectionother

No drug administered, simulation of injection used in same manner as drug